<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OPC-15005802</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2015-01-05</date_registration>
      <primary_sponsor>Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University</primary_sponsor>
      <public_title>Autologous hematopoietic stem cell gene therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy</public_title>
      <acronym />
      <scientific_title>Lentiviral Hematopoietic Stem Cell Gene Therapy for Developped Metachromatic Leukodystrophy and adrenoleukodystrophy</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2015-01-10</date_enrolment>
      <type_enrolment />
      <target_size>1:16;2:16;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=10228</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>I+II (Phase I+Phase II)</phase>
      <hc_freetext>Metachromatic Leukodystrophy; Adrenoleukodystroph</hc_freetext>
      <i_freetext>1:Lentiviral Hematopoietic Stem Cell Gene Therapy;2:No Lentiviral Hematopoietic Stem Cell Gene Therapy;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Lian Qizhou</firstname>
        <middlename />
        <lastname />
        <address>3001 Shungang Road, Futian, Shenzhen, China</address>
        <city />
        <country1 />
        <zip>518035</zip>
        <telephone>+86 18507555077</telephone>
        <email>dalilian2000@aliyun.com</email>
        <affiliation>Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Zhou JiaCai</firstname>
        <middlename />
        <lastname />
        <address>3001 Shungang Road, Futian, Shenzhen, China</address>
        <city />
        <country1 />
        <zip>518035</zip>
        <telephone>+86 0755-83366388-8197</telephone>
        <email>jiacai8199@163.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2 />
    </countries>
    <criteria>
      <inclusion_criteria>For MLD inclusion criteria
1.Confirmed diagnosis as MLD by ARSA genetic diagnosis , MRI imaging and low ARSA A activity ( below 20% or normal level) 
2.The patient' symptoms and lesions   have not been developed to the end stage of MLD.
  
For ALD inclusion criteria
1.Confirmed diagnosis as MLD by ABCD1genetic diagnosis , MRI imaging and high VLCFA level, abnormal highlevel  of adrenocorticotropic hormoneï¼ŒACTH.
2.  The patient' symptoms and lesions   have  not been developed to the end stage of ALD</inclusion_criteria>
      <agemin>1</agemin>
      <agemax>35</agemax>
      <gender>Both</gender>
      <exclusion_criteria>For MLD exclusion criteria. 
1.No clinical symptoms of MLD.
2.ARSA  Activity &gt;50% of healthy controls
3.end stage of MLD
4. Other complications .ie. Cancer.
5.HIV RNA and/or HCV RNA and/or HBV DNA positive patients
6.Patient who underwent allogenic hematopoietic stem cell transplantation with evidence of residual cells of donor origin

For ALD exclusion criteria.
1.No clinical symptoms
2.Normal level of VLCFAs in blood
3.End stage of ALD
4.Other complications .ie. Cancer.
5.HIV RNA and/or HCV RNA and/or HBV DNA positive patients.
6.Patient who underwent allogenic hematopoietic stem cell transplantation with evidence of residual cells of donor origin.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Neural scores;ARSA activity (MLD);VLCFA level ( ALD);</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Taiwan Juridical Association of MLD Care</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-04-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>